PMID- 23560893
OWN - NLM
STAT- MEDLINE
DCOM- 20140422
LR  - 20231213
IS  - 1440-1746 (Electronic)
IS  - 0815-9319 (Linking)
VI  - 28
IP  - 9
DP  - 2013 Sep
TI  - Clinical utility of host genetic IL-28B variants in hepatitis C virus genotype 1 
      Asian patients retreated with pegylated interferon plus ribavirin.
PG  - 1515-20
LID - 10.1111/jgh.12211 [doi]
AB  - BACKGROUND AND AIM: Host interleukin-28B (IL-28B) genetic variants determine a 
      sustained virological response (SVR) in hepatitis C virus genotype 1 (HCV-1) 
      treatment-naive patients. Its impact on treatment-experienced Asian patients with 
      peginterferon/ribavirin in is to be elucidated. METHODS: IL-28B rs8099917 
      genotype was determined in 70 HCV-1 treatment-experienced patients retreated with 
      48-week peginterferon/ribavirin. RESULTS: The SVR rate was 60.0% and was 
      significantly higher in previous relapsers than in nonresponders (72.7% and 
      13.3%, P < 0.001). Multivariate analysis revealed that the most important factor 
      predictive of an SVR was previous relapse (Odds ratio [OR]/95% confidence 
      interval [CI]: 14.76/2.72-80.06, P = 0.002), followed by the carriage of 
      rs8099917 TT genotype (OR/95% C.I.: 7.67/1.27-46.49, P = 0.03). Comparing to 
      patients with TG/GG genotype, those with TT genotype had significantly higher 
      rates of rapid virological response (29.3% vs 0%, P = 0.03), end-of-treatment 
      virological response (86.2% vs 50.0%, P = 0.01), SVR (69.0% vs 16.7%, P = 0.002), 
      and lower relapse rate (22.0 % vs 66.7%, P = 0.04). The SVR rate was similarly 
      low between previous nonresponders with different rs8099917 genotypes (12.5% vs 
      14.3%, P = 1). On the contrary, previous relapsers with rs8099917 TT genotype had 
      a significantly higher SVR rate than those who carried rs8099917 TG/GG genotype 
      (78.0 % vs 20.0%, P = 0.02). Stepwise logistic regression analysis revealed that 
      the only factor predictive of an SVR in previous relapsers was the carriage of 
      rs809997 TT genotype (OR/95% CI:18.50/1.82-188.39, P = 0.014). CONCLUSIONS: Host 
      IL-28B genetic variants played a role in Asian relapsers but not nonresponders 
      retreated with peginterferon/ribavirin. Direct antiviral agents might be possibly 
      avoidable in Asian relapsers with favorable IL-28B genotype.
CI  - (c) 2013 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing 
      Asia Pty Ltd.
FAU - Huang, Chung-Feng
AU  - Huang CF
AD  - Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical 
      University, Kaohsiung, Taiwan; Hepatobiliary Division, Department of Internal 
      Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan; Department of 
      Occupational Medicine, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical 
      University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
FAU - Yeh, Ming-Lun
AU  - Yeh ML
FAU - Hsieh, Meng-Hsuan
AU  - Hsieh MH
FAU - Hsieh, Ming-Yen
AU  - Hsieh MY
FAU - Lin, Zu-Yau
AU  - Lin ZY
FAU - Chen, Shinn-Cherng
AU  - Chen SC
FAU - Wang, Liang-Yen
AU  - Wang LY
FAU - Huang, Jee-Fu
AU  - Huang JF
FAU - Juo, Suh-Hang Hank
AU  - Juo SH
FAU - Lin, Yi-Ching
AU  - Lin YC
FAU - Dai, Chia-Yen
AU  - Dai CY
FAU - Chuang, Wan-Long
AU  - Chuang WL
FAU - Yu, Ming-Lung
AU  - Yu ML
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - Australia
TA  - J Gastroenterol Hepatol
JT  - Journal of gastroenterology and hepatology
JID - 8607909
RN  - 0 (Antiviral Agents)
RN  - 0 (interferon-lambda, human)
RN  - 0 (Interferon alpha-2)
RN  - 0 (Interferon-alpha)
RN  - 0 (Interleukins)
RN  - 0 (Recombinant Proteins)
RN  - 3WJQ0SDW1A (Polyethylene Glycols)
RN  - 49717AWG6K (Ribavirin)
RN  - 9008-11-1 (Interferons)
RN  - G8RGG88B68 (peginterferon alfa-2b)
RN  - Q46947FE7K (peginterferon alfa-2a)
SB  - IM
MH  - Adult
MH  - Antiviral Agents/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Female
MH  - Genotype
MH  - Hepacivirus/*genetics/isolation & purification
MH  - Hepatitis C, Chronic/*drug therapy/*genetics/virology
MH  - Humans
MH  - Interferon alpha-2
MH  - Interferon-alpha/therapeutic use
MH  - Interferons
MH  - Interleukins/*genetics
MH  - Male
MH  - Middle Aged
MH  - Polyethylene Glycols/therapeutic use
MH  - Prognosis
MH  - Recombinant Proteins/therapeutic use
MH  - Recurrence
MH  - Retreatment/methods
MH  - Ribavirin/therapeutic use
MH  - Treatment Outcome
OTO - NOTNLM
OT  - HCV-1
OT  - IL 28B
OT  - re-treatment
EDAT- 2013/04/09 06:00
MHDA- 2014/04/23 06:00
CRDT- 2013/04/09 06:00
PHST- 2013/03/25 00:00 [accepted]
PHST- 2013/04/09 06:00 [entrez]
PHST- 2013/04/09 06:00 [pubmed]
PHST- 2014/04/23 06:00 [medline]
AID - 10.1111/jgh.12211 [doi]
PST - ppublish
SO  - J Gastroenterol Hepatol. 2013 Sep;28(9):1515-20. doi: 10.1111/jgh.12211.